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Abstract
Our previous genome-wide linkage analysis identified a susceptibility locus for generalized vitiligo on 22q12. To search for
susceptibility genes within the locus, we investigated a biological candidate gene, X-box binding protein 1(XBP1). First, we
sequenced all the exons, exon-intron boundaries as well as some 59 and 39 flanking sequences of XBP1 in 319 cases and 294
controls of Chinese Hans. Of the 8 common variants identified, the significant association was observed at rs2269577
(p_trend=0.007, OR=1.36, 95% CI=1.09–1.71), a putative regulatory polymorphism within the promoter region of XBP1. We
then sequenced the variant in an additional 365 cases and 404 controls and found supporting evidence for the association
(p_trend=0.008, OR=1.31, 95% CI=1.07–1.59). To further validate the association, we genotyped the variant in another
independent sample of 1,402 cases and 1,288 controls, including 94 parent-child trios, and confirmed the association by
both case-control analysis (p_trend=0.003, OR=1.18, 95% CI=1.06–1.32) and the family-based transmission disequilibrium
test (TDT, p=0.005, OR=1.93, 95% CI=1.21–3.07). The analysis of the combined 2,086 cases and 1,986 controls provided
highly significant evidence for the association (p_trend=2.94610
26, OR=1.23, 95% CI=1.13–1.35). Furthermore, we also
found suggestive epistatic effect between rs2269577 and HLA-DRB1*07 allele on the development of vitiligo (p=0.033). Our
subsequent functional study showed that the risk-associated C allele of rs2269577 had a stronger promoter activity than the
non-risk G allele, and there was an elevated expression of XBP1 in the lesional skins of patients carrying the risk-associated C
allele. Therefore, our study has demonstrated that the transcriptional modulation of XBP1 expression by a germ-line
regulatory polymorphism has an impact on the development of vitiligo.
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Introduction
Vitiligo (OMIM*193200) is a depigmentary disorder character-
ized by the appearance of white patches as a result of the loss of
functional melanocytes and melanin from skin and hair. It is one of
the most common pigmentation disorders with a prevalence of
0.1% to 2% in different geographic regions and ethnic groups [1].
Clinical and epidemiological investigations indicated that vitiligo is
a multifactorial disorder [2]. The aetiology of vitiligo remains
obscure, but several factors have been implicated in the
development of the disease including self-destructive, biochemical,
neural, autoimmune and genetic susceptibility factors [3].
In the past few years, linkage studies identified several potential
susceptibility loci, such as 1p31(AIS1), 7q(AIS2), 8p(AIS3), and
17p13(VAMAS1) in Caucasian population and 4q13-q21(AIS4),
6p21-p22 and 22q12 in Chinese population [4–8]. A number of
candidate genes were also suggested to be associated with vitiligo,
including HLA, AIRE, VIT1, CAT, FOXD3, ESR1, COMT,
PTPN22 and NALP1 [9–14]. However, most of these candidate
genes are not located within the identified linkage regions,
complicating the interpretation of the significance of these
candidate genes, with the possible exception of the FOXD3 gene
within the AIS1 locus and the NALP1 gene within the VAMAS1
locus in Caucasian population.
Our genome-wide and fine-mapping linkage analyses in the
Chinese families of generalized vitiligo identified a susceptibility
locus on 22q12 [7,8]. Within the 22q12 locus, the linkage evidence
was largely confined to a 10 Mb interval (D22S1167–D22S283)
that contains 84 genes and 35 uncharacterized transcripts,
including X-box binding protein 1 (XBP1). XBP1 encodes a
DNA-binding protein whose downstream target is the X boxes of
HLA DR-a and DP-b [15]. XBP1 acts as a transcription factor by
recognizing the X2 promoter element of both human DR-a and
DP-b. Deletion of X1 and X2 sequences eliminates the expression
of HLA class II genes in vitro and in transgenic mice. With a view
to the autoimmunity feature of vitiligo supported by the significant
PLoS Genetics | www.plosgenetics.org 1 June 2009 | Volume 5 | Issue 6 | e1000523linkage to the MHC region on 6p21-p22 and evidences for the
association of HLA-DR with vitiligo, XBP1 is a strong biological
candidate gene for vitiligo due to its plausible role in the
development of the disease through its interaction with HLA-DR.
Here, we performed a genetic and molecular study of XBP1 in a
Chinese Han population. Through a series of genetic association
and functional analyses, we have provided strong evidence for
XBP1 to be a susceptibility gene for vitiligo.
Results
Direct Sequence Analysis of Exons, Exon-Intron
Boundaries, and 59 and 39 Flanking Sequences
To evaluate the role of regulatory and coding variants within
XBP1 in the development of vitiligo, we sequenced all the 5 exons,
e x o n - i n t r o nb o u n d a r i e sa sw e l la s3 6 2b p5 9 upstream (containing
putative regulatory elements) and 946 bp 39 downstream sequences
of XBP1 in 319 patients of vitiligo and 294 normal controls (Figure
S1). To increase the likelihood of identifying vitiligo susceptibility-
related genetic variants, all the 319 patients were chosen to have a
positive family history of disease, meaning with at least one first-
degree relative carrying the same disease. We identified 34 variants,
including 32 singlenucleotide polymorphisms(SNPs), one single-base
deletion and one three-baseinsertion (TableS1). Of the 34 variants, 9
are known ones (rs2269578, rs2269577, rs2269576, rs2269575,
rs5762809, rs2228260, rs35873774, rs34842534, rs2097461,) report-
ed in the dbSNP database (dbSNP BUILD 129), and 25 are novel
variants (g.2209C.A, g.2186G.A, g.2175C.T, g.2137C.G,
g.2105G.A, g.226T.C, g.214delG, g.17G.C, g.24G.A,
g.27G.T, g.30C.T, g.63–65insGGC, g.129C.T, g.1374A.G,
g.1392C.A, g.1522A.G, g.3352A.G, g.3393A.G, g.3554C.G,
g.3626T.C, g.4262G.A, g.4725G.T, g.4746C.T, g.5409A.G,
g.5597T.C). 8 SNPs (6 known and 2 novel SNPs) were common
with a minor allele frequency of more than 1% in our Chinese Han
samples and were selected for further association analysis (Table 1
and Figure S1).
Association Analysis of 8 Common Variants
Association analysis of the 8 SNPs was performed by using
genotype-based trend and allele tests. Of the 8 SNPs, the
association was only detected at rs2269577 (p_trend=0.007,
OR=1.36, 95%CI=1.09–1.71; Table 1) locating at 197 bp
upstream of the first exon, presumably within the promoter
sequence of XBP1 (Figure S1). As a follow-up, we sequenced the
SNP in additional 365 sporadic patients and 404 healthy controls
and confirmed the association (p_trend=0.008, OR=1.31,
95%CI=1.07–1.59). To further validate this association, we
genotyped rs2269577 in a third independent sample of 1402 cases
and 1288 controls using a TaqMan assay. The second follow-up
analysis provided the further supporting evidence for the
association (p_trend=0.003, OR=1.18, 95%CI=1.06–1.32).
The analysis of the combined 2086 cases and 1986 healthy
controls revealed a highly significant association between
rs2269577 and vitiligo with the minor allele C to be associated
with increased risk (p_trend=2.94610
26, OR=1.23,
95%CI=1.13–1.35; Table 2). Allelic association analysis of the
three samples also provided supporting and consistent evidence for
the association (Table 2). Furthermore, of the 2086 cases analyzed
in this study, there were 94 patients whose parental DNA samples
were collected, allowing us to perform a family-based association
analysis (TDT) that believe to be more robust than population-
based case-control analysis. The TDT analysis of rs2269577
revealed a significant evidence for the over-transmission of the C
allele to the affected individuals (T:U 52:27, p=0.005, OR=1.93,
95%CI=1.21–3.07). Taking together, our progressive association
analysis in three independent samples provided strong evidence for
the association between rs2269577 and vitiligo susceptibility in the
Author Summary
Vitiligo is a genetically complex skin disorder that afflicts
0.1%–2% of the population throughout the world. Linkage
and association studies in different populations have
implicated several genomic regions and candidate genes
that are linked to the development of vitiligo. Our previous
genome-wide linkage analysis identified a genetic suscep-
tibility locus for vitiligo on 22q12 in a Chinese population.
In this study, we conducted a genetic and molecular study
of a biologically plausible candidate gene, XBP1, within the
region. We first performed a progressive association
analysis in three independent samples of vitiligo, which
revealed significant association between a putative
promoter polymorphism, rs2269577, and vitiligo. Then,
our functional analysis also demonstrated that the risk-
associated allele of this variant has a stronger promoter
activity and was associated with a significantly elevated
expression of XBP1 in lesional skins in patients carrying the
risk-associated allele. Our findings have provided the first
evidence for XBP1 to play an important role in the
development of vitiligo.
Table 1. Association analysis of 8 common SNPs within the coding and promoter sequences of XBP1 in the initial 319 cases and
294 controls.
SNP Alleles Position Location Cases (319) Controls (294) P_trend OR(95% CI)
(MAF) (MAF)
rs2269578 CRG 8587412 promoter 0.18 0.22 0.06 0.77 (0.58–1.01)
XBP1snp1 CRA 8587338 promoter 0.03 0.04 0.35 0.74 (0.40–1.40)
rs2269577 GRC 8587326 promoter 0.41 0.34 0.007 1.36 (1.09–1.71)
XBP1snp10 GRT 8587103 59UTR 0.06 0.06 0.80 0.94 (0.59–1.50)
rs2269575 CRT 8587095 59UTR 0.26 0.28 0.53 0.93 (0.73–1.18)
rs5762809 GRA 8587063 exon1 0.18 0.21 0.18 0.83 (0.62–1.10)
rs2228260 CRT 8586875 exon1 0.09 0.07 0.40 1.20 (0.79–1.82)
rs2097461 GRA 8582448 intron4 0.42 0.38 0.16 1.18 (0.93–1.50)
doi:10.1371/journal.pgen.1000523.t001
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control samples were found to be in Hardy-Weinberg equilibrium
(HWE) (p values.0.05), and the genotypes of rs2269577 were also
found to be in HWE in the controls of the two follow-up samples
(p values$0.05).
Stratified Association Analysis of rs2269577 by Clinical
Subtypes
To further investigate the association at rs2269577, we
performed the stratified association analysis in different patient
subgroups by age of onset, family history, severity of disease (body
surface involvement) and association with autoimmune disorders.
The results were summarized in Table 3. Rs2269577 was found to
be associated with the severity of disease. Patients carrying the risk
allele are more likely to show extensive body surface involvement
(.20%) than limited body surface involvement (,20%)
(OR=1.65, p=0.02). We did not see the association of
rs2269577 with age of onset, family history and the related
autoimmune disorders.
Analysis of Interaction between rs2269577 and HLA-
DRB1*07
Given the possible functional interaction between XBP1 and
HLA-DR, we investigated whether the genetic effect at rs2269577
is modified by the HLA-DR risk allele for vitiligo. We successfully
genotyped the DRB4*01, DRB1*04, DRB1*07, DRB1*12 alleles
by PCR-SSP in 1755 cases and 1742 controls and found the HLA-
DRB1*07 allele to be significantly associated with vitiligo
(p=4.53610
221, OR=1.98, 95%CI=1.72–2.29, Table S3). We
then tested the epistatic interaction between rs2269577 and HLA-
DRB1*07 using logistic regression analysis and found that the full
model with both the main and interactive effects was better than
the model with only the main effect to fit the data (p=0.033).
Furthermore, we performed the stratified association analysis of
rs2269577 by HLA-DRB1*07 allele. The association at rs2269577
was significant in both the patients carrying and not carrying the
HLA-DRB1*07 allele (Table 4). However, the association seems to
be stronger in the patients carrying the HLA-DRB1*07 allele. For
example, the C/G genotype of rs2269577 showed a significant
association with increased risk in the patients carrying the HLA-
DRB1*07 allele (OR=1.44, p=0.007), but did not show the
association in the patients not carrying the allele (OR=0.94,
p=0.496). The CC genotype of rs2269577 also showed a stronger
association in the carriers of the HLA-DRB1*07 allele (OR=2.05)
than in the patients not carrying the allele (OR=1.58), but the
difference is not statistical significant.
Molecular Analysis of rs2269577 and XBP1 Expression
Because rs2269577 is located at the promoter region of XBP1,
we performed a series of functional analysis to evaluate the SNP’s
impact on gene expression. First, we performed an in-vitro reporter
assay analysis to evaluate whether the promoter sequences
carrying different SNP alleles have differential promoter activity.
We cloned the promoter sequences of XBP1 carrying different
SNP alleles into luciferase reporter vectors (pGL3) and then
transiently transfected the two reporter vectors into the HaCat and
Mel-RM cells. Luciferase activity was measured after 48 hrs
incubation. As shown in Figure 1, the cloned promoter sequence
carrying the risk-associated C allele can strongly induce the
expression of the reporter gene, whereas the cloned promoter
sequence carrying the wild-type G allele show a much weaker, if
any, induction of the reporter gene expression. In both cell lines,
the difference in the induction of the reporter gene expression
between the two alleles is statistically significant (P,0.05).
Table 2. Summary of the association results for rs2269577 in three independent samples as well as the combined sample.
Number Allele (Frequency ) Genotype (Frequency) P_allele P_trend OR (95% CI)
C G C/C C/G G/G
Initial Sequence Analysis Cases 319 264 (0.41) 374 (0.59) 57 (0.18) 150 (0.47) 112 (0.35) 0.005 0.007 1.36 (1.09–1.71)
Controls 294 198 (0.34) 390 (0.66) 41 (0.14) 116 (0.39) 137 (0.47)
Follow-up By Sequencing Cases 365 298 (0.41) 432 (0.59) 81 (0.22) 136 (0.37) 148 (0.41) 0.005 0.008 1.31 (1.07–1.59)
Controls 404 274 (0.34) 534 (0.66) 45 (0.11) 184 (0.46) 175 (0.43)
Follow-up By TaqMan Cases 1402 1195 (0.43) 1609 (0.47) 271 (0.19) 653 (0.47) 478 (0.34) 0.002 0.003 1.18 (1.06–1.32)
Controls 1288 993 (0.39) 1583 (0.62) 187 (0.15) 619 (0.48) 482 (0.37)
Combined Analysis Cases 2086 1757 (0.42) 2415 (0.58) 409 (0.20) 939 (0.45) 738 (0.35) 2.01610
26 2.94610
26 1.23 (1.13–1.35)
Controls 1986 1465 (0.37) 2507 (0.63) 273 (0.14) 919 (0.46) 794 (0.40)
OR: per allele odds ratio from trend test.
doi:10.1371/journal.pgen.1000523.t002
Table 3. Stratified association analysis of rs2269577 by
clinical subgroups.
Genotype
Samples Total CC CG GG OR 95%CI P
Age of onset
#20 years 1241 269 536 436 1.12 0.99–1.26 0.07
.20 years 813 136 384 293
Family history
Familial 487 91 239 157 1.06 0.92–1.21 0.45
Sporadic 1592 318 695 579
Body surface involvement
.20% 40 11 20 9 1.65 1.07–2.54 0.02
#20% 1167 236 634 528
Associated autoimmune disorders
With 71 9 39 23 0.99 0.71–1.38 0.95
Without 1314 238 585 491
OR and P were from the comparison between the clinical subgroups by using
the trend test.
doi:10.1371/journal.pgen.1000523.t003
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paired lesional and non-lesional skins from 38 patients by using
quantitative real-time PCR analysis. Overall, there was a moderate
but statistically significant increased level of XBP1 mRNA in the
lesional skins compared with the non-lesional skins of patients
(p=0.0007, Figure 2).More interestingly, the elevated expression of
XBP1 mRNA in the lesional skin seemed to be correlated with
rs2269577’s genotypes (Figure 3). The elevated expression of XBP1
mRNA in the lesional over the non-lesional skins was only observed
in the patients carrying either one (average fold difference=3.61,
p=0.0004) or two copies of the risk-associated C allele (average fold
difference=4.80 p=0.07). In contrast, in the patients not carrying
risk-associated allele (with GG genotype), there was no difference in
mRNA level between the lesion and normal skins (average fold
difference=1.39,p=0.93).Theaveragefold differencebetweenthe
pairedlesionalandnon-lesionalsamplesinthepatientscarryingGG
genotype (average fold difference=1.39) was significantly lower
than the average fold difference in the patients carrying either GC
or CC genotypes (average fold difference=3.88) (p=0.003).
Therefore, both the in-vitro and in-vivo transcriptional analyses
provided consistent results, indicating that the risk-associated C
allele is associated with a higher expression of XBP1 (than the wild-
type G allele) which in turn is associated with the lesion
development in vitiligo patients.
We also performed immunohistochemistry analysis using
formalin-fixed paraffin embedded skin biopsy samples from
another 37 patients to assess the XBP1 protein level in the
lesional and non-lesional skins. As shown in Figure 4 and Figure 5,
there was a moderately enhanced XBP1 antibody staining in the
lesional skin compared to the non-lesional skin (p=0.003).
Furthermore, the enhanced staining of XBP1 antibody in the
lesional skin is more prominent in the patients carrying either CC
(p=0.04) or GC (p=0.03) genotype. In the patients carrying the
GG genotype, there was no significant enhancement (p=0.41). An
example of the enhanced XBP1 antibody staining in the lesional
over the non-lesional skin of a patient is provided in Figure 6.
Discussion
To search for susceptibility gene(s) within a genomic region
showing a strong linkage to vitiligo, we interrogated a biologically
plausible candidate gene, XBP1, within the region through a series
of genetic association and molecular analyses. The progressive
genetic association analysis in three clinical samples of vitiligo
provided strong evidence for the association between a putative
promoter polymorphism, rs2269577 (2197G.C to the first exon),
and vitiligo susceptibility in the Chinese Han population. Our
subsequent functional analysis has further demonstrated a
Table 4. Logistic Regression odds ratio estimates of XBP1 genotype stratified by HLA-DRB1*07 in 3497 samples.
HLA-DRB1*07
+ 2
Genotype OR 95% CI P OR 95% CI P
XBP1 G/G 1.00 1.00
rs2269577 C/G 1.44 1.10–1.87 0.007 0.94 0.78–1.12 0.496
C/C 2.05 1.46–2.88 3.19610
25 1.58 1.23–2.02 2.85610
24
OR is compared to the reference genotype.
doi:10.1371/journal.pgen.1000523.t004
Figure 1. Difference of the promoter activity between the G and C allele of rs2296577 in Mel-RM cells and HaCat cells. Each column
represents mean6s.d. of at least three experiments. *Two-tailed P,0.05 by Student’s t-test.
doi:10.1371/journal.pgen.1000523.g001
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associated C allele has a stronger promoter activity (than the wild-
type G allele) and may induce a higher expression of XBP1, which
in turn promotes the development of lesions in vitiligo patients.
Therefore, we have demonstrated that the transcriptional
modulation of XBP1 expression by germ-line regulatory polymor-
phisms can influence the development of vitiligo.
HLA genes have been shown to be associated with vitiligo.
Although the results of previous studies are generally moderate
and variable, the evidence for the association of HLA-DR alleles
with vitiligo was demonstrated in several different populations.
HLA-DRB1*03, HLA-DRB1*04 and HLA-DRB1*07 alleles were
found to be associated with vitiligo in Turkish patients, and the
association of HLA-DRB4*0101 and HLA-DRB4*0303 alleles
was found in Dutch patients [16,17]. Furthermore, Fain et al
found that in multiplex vitiligo families, the HLA-DRB1*04-HLA-
DQB1*0301 haplotype is associated with both an increased risk of
vitiligo and the early onset of the disease [18]. Our previous
linkage analysis also implicated the linkage to 6p21-p22 with a
NPL value above 4 [8]. Given XBP1’s known function as a
transcription factor controlling the expression of HLA-DR, we
posit that XBP1 may influence the development of vitiligo, at least
Figure 2. XBP1 mRNA expression in the paired lesional and non-lesional skins from 38 patients. XBP1 mRNA was measured by using
quantitative real-time PCR. Data represent the normalized XBP1 mRNA expression level by 18S rRNA. The normalized expression data was
standardized so that the average of the normalized expression in the non-lesional skins is equal to 1. The comparison of XBP1 mRNA expression
between the 38 paired lesional and non-lesional skins were performed by using nonparametric Wilcoxon Signed Ranks Test.
doi:10.1371/journal.pgen.1000523.g002
Figure 3. Relative expressions of XBP1 in the lesional and non-lesional skins (fold) of three patient groups with different genotypes
of rs2269577: 12 patients with GG genotype, 20 patients with GC genotype, and 6 patients with CC genotype. The Avg. indicates the
mean of the difference between the paired lesional and non-lesional skins within each of three genotypes. The y axis is in log2 scale.
doi:10.1371/journal.pgen.1000523.g003
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Consistent with this hypothesis, we indeed observed the evidence
for the modification of the genetic effect at rs2269755 by the risk
allele HLA-DRB1*07 and the epistatic interaction between the
two risk alleles in the Chinese Han population. However, due to
their moderate significance, our results on the interaction between
XBP1 and HLA-DRB1 risk alleles need to be validated by
additional studies in large samples.
Rs2269577 was first found to be associated with bipolar
affective disorder in Japanese patients and over-transmitted to
affected offspring in trios of NIMH Bipolar Disorder Genetic
Initiative [19]. The follow-up studies of the SNP in diverse
populations, however, provided inconsistent results [20–22]. The
SNP was also suggested to be associated with schizophrenia [23–
26]. Intriguingly, the common G allele was found to be associated
with a reduced promoter activity of XBP1 and increased
susceptibility to bipolar disorder in the previous study [19],
whereas the G allele was found to be associated with a reduced
promoter activity but a decreased susceptibility to vitiligo in our
study. Upon the confirmation by further studies, these results
indicate that the transcriptional modulation of XBP1 function may
lead to different physiological outcome. XBP1 has a diverse
biological function. It was found to be widely expressed and is
essential for fetal survival, hepatogenesis, neurological develop-
Figure 4. XBP1 protein level determined by immunohistochemical staining in the paired lesional and non-lesional skins from 37
patients with vitiligo. Data represent the percentage of positive cells. The comparison of XBP1 protein level between the 37 paired lesional and
non-lesional skins was done by using Paired Samples T Test.
doi:10.1371/journal.pgen.1000523.g004
Figure 5. The difference of XBP1 protein level (fold) between the paired lesional and non-lesional skins in three groups of patients
with different genotypes of rs2269577: 7 patients with GG genotype, 24 patients with GC genotype, and 6 patients with CC
genotype. The Avg. indicates the mean of the difference between the paired lesional and non-lesional skins within each of three genotypes.
doi:10.1371/journal.pgen.1000523.g005
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[27,28]. It was also shown to be required for the development of
highly secretory cells such as plasma cells and pancreatic and
salivary gland epithelial cells and adaptation of tumor cells to
hypoxic conditions [29–31] and the mammalian unfolded protein
response (UPR) or endoplasmic reticulum (ER) stress response
[32]. As a transcription factor, it regulates functionally distinct
targets, including MHC class II genes, through different sequence
motifs and often in cell type, cell cycle and tissue specific fashion
[33–35]. Consistent to its diverse biological function, XBP1 has
also been shown to be involved in many disorders including
diabetes, inflammatory bowel disease, bipolar disorder, schizo-
phrenia and multiple myeloma [19,24,36–38]. Therefore, the
diverse physiological outcome from the transcriptional modulation
of XBP1 by same germ-line mutations is biologically plausible.
There are several limitations that need to be considered for
interpreting the results of this study. First, the sample size of our
study is moderate, which has limited our study to the common
variants. The moderate sample size is also likely responsible for the
moderate significance of our results for gene-gene interaction.
Furthermore, the contribution of a genetic risk variant to disease
development is influenced by both the genetic effect and the
population frequency of the risk variant that often vary from
population to population. Therefore, the results from the current
study need to be validated by additional studies in larger samples
of diverse populations. Second, although the coding sequences of
XBP1 were well covered in the sequencing and genetic association
analyses, the coverage of the promoter sequences is rather limited.
Consequently, other regulatory risk variants may have been
missed in this study. Furthermore, although our molecular
analyses do support rs2269577 to be functional and thus causal,
the functional results are generally suggestive and can be further
improved. For example, the quantification of the XBP1 antibody
staining was done manually, largely due to the limited resource
available for the current study, and can be improved by
morphometric analysis that digitally analyzes the levels of
immunohistorchemical staining. Therefore, further functional
studies and fine mapping analyses will be needed to validate the
current results.
In conclusion, we found a common regulatory variant,
rs2269577, in the promoter region of XBP1 that is associated
with increased risk for vitiligo by carrying out a series of
association analysis in three independent samples of the Chinese
Han population. We further demonstrated that the association is
probably due to the transcriptional modulation of XBP1
expression which was shown to be important for the development
of vitiligo lesion. Our findings have therefore not only provided
insight into the genetic basis of vitiligo but also advanced our
understanding on XBP1’s function.
Materials and Methods
Subjects
A total of 4260 individuals were included in this study,
consisting of 2086 vitiligo patients, 1986 unrelated healthy controls
and 94 parent-child trios. Samples were respectively collected from
the Department of Dermatology at First Affiliated Hospital of
Anhui Medical University at Hefei, Anhui, China, the Vitiligo
Clinic of the Railway Hospital at Xiangfan, Hubei, China, and the
Department of Dermatology at Affiliated Xijing Hospital of
Fourth Military Medical University at Xian, Shanxi, China. The
diagnosis of vitiligo was made on the basis of the presence of
typical clinical features (discrete, well-circumscribed depigmented
patches), and only patients with clear signs of acquired patches on
the trunk, extremities, central face, genitalia, or other area was
scored as affected. Consensus diagnosis of vitiligo was performed
by two experienced dermatologists who carefully checked
phenotypes by history, lesion maps, physical examination and/or
photographs. Any individual whose phenotype was questionable
was excluded from the study. All controls were healthy individuals
without vitiligo, any autoimmune disorders (such as psoriasis,
Graves’disease, Systemic lupus erythematosus, Rheumatoid ar-
thritis, etc), systemic disorders, and any family history of vitiligo
(including first-, second- and third-degree relatives) and recruited
from health check-up centers. All the cases and controls are self-
declared Chinese Han and were collected from the same
geographic regions of China. Cases and controls were matched
on gender. The cases (average age=25.70614.36 years) were
younger than the controls (average age=31.95615.72 years), but
the difference is very moderate. Approval to undertake this study
was granted by the Ethics Committee of the Anhui Medical
University and was conducted according to the Declaration of
Helsinki Principles. Written informed consent was obtained from
each recruited subject.
Sequence Analysis and SNP Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
using a standard procedure [39]. We designed primers flanking the
Figure 6. Immunohistochemical staining of XBP1 protein in the paired lesional (A,B) and non-lesional skin (C,D) of a patient with
vitiligo (magnifications: (A,C)6200; (B,D)6400).
doi:10.1371/journal.pgen.1000523.g006
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of its putative promoter and 946 bp sequence downstream from
the 39 end of XBP1 gene by using the web-based version of the
Primer 3.0 program (http://primer3.sourceforge.net/). Primer
sequences were listed in Table S2. Products were amplified by
polymerase chain reactions (PCR) with touchdown program(95uC
for 15 min; 40 cycles of 94uC for 40 s, 57uC for 60 s, 72uC for
70 s, 72uC for 10 min, except that in the first 12 cycles the
annealing temperature decreased from 63uCt o5 7 uC by 0.5uC per
cycle). PCRs were carried out in an ABI 9700 Thermal Cycler in
10 ml reaction volume containing 20 ng of genomic DNA,
0.3 mM dNTPs, 0.3 mM of each primer, 3.0 mM MgCl2 and
0.1 units of Hotstar Taq DNA polymerase (Qiagen). After the
amplification, products were purified using a QIAquick PCR
Purification Kit (Qiagen) and directly sequenced on ABI
PRISM(R) 3730 automated sequencer (Applied Biosystems). All
the variants identified by sequence analysis were checked against
the dbSNP data (version 129) for determining the novelty of
variants, and the novel variants were named according to their
positions to the first exon of the gene.
SNP genotyping was performed using the 59 nuclease allelic
discrimination assay (TaqMan Assay) on an ABI PRISM 7900HT
Sequence Detection System. The primers and the discrimination
probes were designed and purchased from GeneCore (Shanghai,
China). PCR reactions were performed in 384-well plates, each
well containing 20 ng DNA, 5 mlo f2 6TaqMan Universal PCR
Master Mix, 0.9 mM of each primer, 0.25 mM of each probe.
Automatic allele calling was performed by ABI PRISM 7900HT
data collection and analysis software, version 2.1.
HLA-DR Alleles Typing
Polymerase chain reaction/sequence specific primer (PCR/SSP)
method was used for analyzing HLA-DR alleles. We genotyped
DRB4*01, DRB1*04, DRB1*07, DRB1*12 alleles, which amplify-
ing primers were described by Olerup et al [40]. Control primers
giving rise to a 796-bp fragment from the third intron of HLA-
DRB1 were included in all PCR reactions as positive control for
PCR amplification. PCRs were performed with a touchdown
program in a 10 ml reaction that contained 20 ng of genomic DNA,
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 0.3 mM dNTPs, 3.0 mM
MgCl2, 0.3 mM of the allele and group-specific primers, 0.06 mMo f
the control primers, and 0.1 units of Hotstar Taq DNA polymerase
(Qiagen). PCR conditions were: Taq activation at 95uC for
15 minutes, followed by 37 cycles, each having denaturation at
94uC for 20 seconds, annealing at 58uC for 30 seconds and
extension at 72uC for 60 seconds, except that in the first 12 cycles,
the annealing temperature decreased from 64 to 58uC by 0.5uC per
cycle, and the final extension was 10 minutes. PCR products were
electrophoresed in2.0% agarose gelcontaining0.5 mg/ml ethidium
bromide. Gels were run for 40 min at 5 V/cm in 0.56TBE buffer
(89 mM Tris base, 89 mM boric acid and 2 mM EDTA, pH 8.0).
Gels were visualized using Gel Documentation and Analysis
(Advanced American Biotechnology, Fullerton, CA, USA) after
electrophoresis.
Luciferase Assay Analysis
We amplified a 1132-bp fragment (21017 to +115 bp from the
first exon) of XBP1 by PCR and cloned it into the KpnI/HindIII
site of pGL3-Basic vector (Promega). We constructed two reporter
plasmids, carrying either 2116C (pGL3-C) or 2116G allele
(pGL3-G) of rs2269577. The allele status of the reporter plasmid
was confirmed by sequencing. We transfected Human keratino-
cyte HaCat cells and melanoma Mel-RM cells with the pGL3-
basic vector (control without the cloned promoter sequence) or the
reporter plasmid (pGL3-C or pGL3-G). pRL-SV40 plasmid
(Promega) was used as an internal control for transfection
efficiency. After 48 hours of incubation, cells were harvested and
analyzed for luciferase activity using the Dual-Luciferase Reporter
Assay System (Promega). All transfections were carried out in
triplicate.
Real-Time Quantitative RT–PCR Analysis
Human skin biopsies (3 mm) were collected in the Department
of Dermatology at First Affiliated Hospital of Anhui Medical
University, Hefei, Anhui, China with informed consent. Paired
biopsies were obtained from each of 38 patients: one from the
lesional skin (at least 2 cm from the lesional boarders), the other
from the symmetrical normal skin (also more than 2 cm from the
lesional boarders). Total RNA was isolated by using RNeasy Mini
kit (Qiagen) with treatment of DNase, according to the
manufacturer’s instructions. We carried out reverse transcription
according to the Superscript protocol (TaKaRa). Real-time PCR
was performed using the iCycler (Bio-Rad). Reactions were
performed in a 10-ml volume including diluted cDNA samples,
primers, and SYBR Green I Mastermix (TaKaRa). For real-time
PCR analysis, XBP1 was amplified with forward primer 59-
TGAGCTGGAACAGC AAGTGGT-39 and reverse primer 59-
CCCAAGCGCTGTCTTAACTCC-39. 18 s RNA served as an
endogenous control and was amplified with forward primer 59-
GTAACCCGTTGAACCCCATT -39 and reverse prime 59-
CCATCCAATCGGTAGTAGCG -39. Dissociation curve analy-
ses were performed to confirm specificity of the SYBR Green
signals in each experiment. Real-time PCR data were collected
using iCycler software (version 3.1, Bio-Rad). Both 18 s RNA and
XBP1 were tested in triplicate for each sample. The measurement
(Ct value) of XBP1 expression was normalized by using 18 s’
measurement (Ct value). For the overall comparison of XBP1
expression between the lesional and non-lesional skins, all the
normalized measurements (DCt) were standardized so that the
average of the DCts of non-lensional skin samples was equal to 1.
For the comparison of XBP expression between the paired lesional
and non-lesional samples from same patients, the normalized
measurements (DCt) were used to calculate the difference (DDCt)
between the lesional and non-lesional skin samples from the same
patient. The fold change in the expression level was calculated by
using the formula of 2
DDCt.
Immunohistochemistry Analysis
Lesional and non-lesional skin samples were collected (as the
same as above) from another 37 patients, and fixed in formalin.
Fixed tissues were embedded routinely in paraffin, serially sectioned
at 5 mm, and placed on poly-L-lysine coated slides for immunohis-
tochemistry with an ABC Staining kit (Santa Cruz Biotechnology,
CA, USA) in accordance with the manufacturer’s instructions. The
sections were de-paraffinized, rehydrated and reacted overnight at
4uC with the primary Rabbit anti-human XBP1 polyclonal
antibody (ab37152, abcam, CA, USA) at a dilution of 1:200. The
biotin-labeled secondary antibody (sc-2491, Santa Cruz Biotech-
nology, CA, USA) was added at a dilution of 1:100. Diamino-
benzidine(DAB) was used forstainingdevelopment and thesections
were counterstained with haematoxylin. The staining intensity and
the percentage of positive cells were evaluated using regular light
microscopy by two observers who wereblind to the clinical data (the
lesion or the normal) independently.
Statistical Analysis
We performed Armitage Trend test to assess genotype-
phenotyoe association as well as allelic association analysis using
Regulatory Variation in XBP1 and Vitiligo
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samples was performed using Cochran-Mantel-Hanezel stratifica-
tion analysis [42]. Hardy-Weinberg proportion was tested in
control samples to ensure genotyping quality. The TDT analysis
was performed to test association in case-parent triad data using
the Haploview version 3.2 [43]. The comparison between the
clinical subgroups was performed by testing the association of
rs2269577 with clinical sub-phenotypes using genotype-based
trend test. Interaction analysis was performed by comparing the
logistic regression model of only main effect against the model of
both the main and interactive effects. Chi-square test was used for
estimating the significance of the statistics of the log-likelihood
ratio test. To examine the pattern of the interaction, we performed
the analysis of XBP1 gene stratified by HLA positive and negative.
Student’s t test was used to examine the differences in luciferase
reporter gene expression. Differences in mRNA level of XBP1
between lesional and normal skins (in all the patients as well as
within different genotype groups) were tested for significance with
the nonparametric Wilcoxon signed-rank test. Correlation be-
tween mRNA levels of XBP1 and genotype (GG vs GC+CC) was
analyzed using Mann-Whitney U test. Differences in protein level
between lesional and normal skins within different genotype
groups were tested using Paired Samples T Test. All the statistical
analyses were done in SPSS 10.0.
Supporting Information
Figure S1 Genomic structure of the XBP1 gene with the
location of 8 SNPs subjected to genetic association analysis. The
gray bars (underneath the genomic structure) indicate the genomic
regions that were amplified for sequencing analysis.
Found at: doi:10.1371/journal.pgen.1000523.s001 (1.34 MB TIF)
Table S1 A list of all the variants identified by the initial
sequencing analysis of XBP1.
Found at: doi:10.1371/journal.pgen.1000523.s002 (0.07 MB
DOC)
Table S2 Primers used for the sequencing analysis of the exons,
exon-intron boundaries, and some promoter sequences of XBP1.
Found at: doi:10.1371/journal.pgen.1000523.s003 (0.03 MB
DOC)
Table S3 Frequencies of HLA-DR alleles in vitiligo patients
compared with control group.
Found at: doi:10.1371/journal.pgen.1000523.s004 (0.03 MB
DOC)
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